Skip to main content
NewslettersWatchlist

Metsera Inc(MTSR-Q)
NASDAQ

Today's Change
Delayed Last Update
Day Low70.13
Day High70.78
Open:70.74
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Metsera Inc

Select a category then submit the form to load news
Motley Fool
Can AI Drive Peloton's Comeback?
Motley Fool
Down 55%, Should You Buy the Dip on Pfizer?
Motley Fool
Is Pfizer Stock a Buy After This $10 Billion Acquisition?
Tipranks
Metsera, Inc. Completes Merger and Restructures Leadership
Motley Fool
Why Is Everyone Talking About Novo Nordisk Stock?
Business Wire
Pfizer Completes Acquisition of Metsera
Motley Fool
Should You Forget Pfizer and Buy This Magnificent Drug Stock Instead?
Motley Fool
Why Metsera's Share Price Is Plummeting This Week
Motley Fool
Where Will Pfizer Be in 3 Years?
Tipranks
Metsera Amends Merger Agreement with Pfizer
Motley Fool
Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?
Tipranks
Metsera Considers Novo Nordisk’s Superior Acquisition Proposal
SYNDTGAM
Wegovy maker Novo Nordisk cuts guidance again but Medicare pricing deal uplifts investors
A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. REUTERS/Tom Little
Motley Fool
Here's Why Shares in Viking Therapeutics Shot Higher in October
Tipranks
Metsera, Inc. Responds to Pfizer’s Litigation Claims
Motley Fool
Did Novo Nordisk Just Say "Checkmate" to Pfizer?
Motley Fool
Meet the 7% Yield Dividend Stock That Could Soar in 2026
Motley Fool
Is It Time to Dump Your Shares of Pfizer?
Business Wire
Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
Tipranks
Metsera Considers Novo Nordisk’s Superior Proposal
Business Wire
Pfizer Addresses Proposal for Metsera
Motley Fool
2 High-Yield Stocks With Fresh Catalysts
Tipranks
Metsera’s MET097 Study: A Potential Game-Changer in Obesity and Diabetes Treatment
Tipranks
Metsera’s New Phase 1 Study: A Potential Game-Changer in Obesity Treatment
Motley Fool
Google Parent Alphabet Has $754 Million Invested in These 3 Hot Growth Stocks. Here's the 1 Wall Street Likes the Most.
Motley Fool
2 Unstoppable Dividend Stocks Yielding More Than 4% That Income-Seeking Investors Will Want to Buy in November and Hold Forever
Business Wire
Metsera Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR
Motley Fool
2 Mega-Dividend Stocks With Yields As High As 7%
Tipranks
Metsera, Inc. Announces Special Meeting for Merger Vote with Pfizer
Motley Fool
Down 44%, Should You Buy the Dip on Viking Therapeutics?
Motley Fool
Where Will Pfizer Be in 5 Years?
Motley Fool
Down 50%, Should You Buy the Dip on Pfizer?

Profile

Metsera Inc. is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight and related conditions. Metsera Inc. is based in NEW YORK.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.